Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 4, 2006, Pages 427-433

  Heresbach, Denis ^a   Manfredi, Sylvain ^a   D'Halluin, Pierre N ^a   Bretagne, Jean François ^a   Branger, Bernard ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Colorectal cancer; Colorectal cancer screening; Faecal occult blood test; Meta analysis

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GENETIC HETEROGENEITY; HEALTH PROGRAM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TIME SERIES ANALYSIS;

AGED; COLORECTAL NEOPLASMS; DENMARK; FEMALE; FRANCE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; UNITED STATES;

EID: 33645106477     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200604000-00018     Document Type: Conference Paper

References (61)

1. Mandel J, Bond J, Church T, Snover D, Bradley G, Schuman L, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328:1365-1371.
2. Hardcastle J, Chamberlain J, Robinson M, Moss S, Amar S, Balfour T, et al. Randomised controlled trial of faecal-blood screening for colorectal cancer. Lancet 1996; 348:1472-1477.
3. Kronborg O, Fenger C, Olsen J, Jorgensen O, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471.
4. Bretagne J, Faivre J. The French Society of Gastroenterology recommends an organized national screening for colorectal cancer [in French]. Gastroenterol Clin Biol 2000; 24:492-493.
5. Anonymous. European Union recommendations for colorectal cancer screening [in French]. Bull Cancer 2001; 88:687-692.
6. Classen M. ESGE workshop on colorectal cancer screening: summary and outlook. Endoscopy 2004; 36:366-368.
7. Jorgensen O, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29-32.
8. Faivre J, Tazi M, El Mrini T, Lejeune C, Benhamiche A, Dassonville F. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Br J Cancer 1999; 79:680-683.
9. Faivre J, Dancourt V, Lejeune C, Tazi M, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126:1674-1680.
10. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317:559-565.
11. Mandel J, Church J, Ederer F, Bond J. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91:434-437.
12. Mandel J, Church T, Bond J, Ederer F, Geisser M, Mongin S, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343:1603-1607.
13. Scholefield J, Moss S, Sufi F, Mangham C, Hardcastle J. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002; 50:840-844.
14. Kronborg O, Jorgensen O, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004; 39:846-851.
15. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,000 subjects. Cancer 1988; 62:645-651.
16. Cucherat M. Software for meta-analysis of clinical trials. Easy-MA. Available at: www.spc.univ-lyon.fr/mcu/easyma/. Accessed: 2001.
17. Moayyedi P. Meta-analysis: can we mix apples and oranges? Am J Gastroenterol 2004; 99:2297-2301.
18. Fischbach L, Goodman K, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31:128-139.
19. Imperiale T, Wagner D, Lin C, Larkin G, Rogge J, Ransohoff D. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002; 346:1781-1785.
20. Imperiale T, Ransohoff D, Itzkowitz S, Turnbull B, Ross M, for the Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704-2714.
21. Hosek R, Flanders W, Sasco A. Bias in case-control studies of screening effectiveness. Am J Epidemiol 1996; 143:193-201.
22. Kerlikowske K, Grady D, Rubin S, Sandrock C, Ernster V. Efficacy of screening mammography. A meta-analysis. JAMA 1995; 273:149-154.
23. Nyström L, Rutqvist L, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993; 341:973-978.
24. Gotzsche P, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355:129-134.
25. Duffy S. Interpretation of the breast screening trials: a commentary on the recent paper by Gotzsche and Olsen. Breast 2001; 10:209-212.
26. French Agency of Healthcare Evaluation. Breast cancer screening with mammography: comments on the meta-analysis from Gotzsche and Olsen [in French]. Available at: www.ANAES.fr. Accessed: 11 February 2002.
27. Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352:609-613.
28. Schulz K, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-412.
29. Miller A, Baines C, To T, Wall C. Screening mammography re-evaluated. Lancet 2000; 355:747-751.
30. Uhry Z, Fourme E, Jougla E, Cheri-Challine L, Ancelle-Park R, Bazin B, et al. Breast cancer mortality in administrative districts using organized screening since 1990 [in French]. Bull Épidémiol Hebdomadaire 2003; 19-22.
31. Tazi M, Faivre J, Dassonville F, Lamour J, Milan C, Durand G. Participation in faecal occult blood screening for colorectal cancer in a well defined French population: results of five screening rounds from 1988 to 1996. J Med Screening 1997; 4:147-151.
32. Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buémi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004; 28:877-881.
33. Remontet L, Estève J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003; 51:3-30.
34. Benhamiche AM. Colon cancer: epidemiology and high-risk group definition [in French]. Gastroenterol Clin Biol 1998; 22:S3-S11.
35. Schoenfield P, Brooks C, Flood A, Dobhan R, Eastone J, Coyle W, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352:2061-2068.
36. Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler D, Dhom G. Long-lasting reduction of risk of colorectal cancer following screening endoscopy. Br J Cancer 2001; 85:972-976.
37. Atkin W, Morson B, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326:658-662.
38. Müller A, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-controlled study of 32,702 veterans. Ann Intern Med 1995; 123:904-910.
39. Müller A, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155:1741-1748.
40. Newcomb P, Norfleet R, Storer B, Surawicz T, Marcus P. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84:1572-1575.
41. Newcomb P, Storer B, Morimoto L, Templeton A, Potter J. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003; 95:622-625.
42. Investigators of the UK Flexible Sigmoidoscopy Screening Trial. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359:1291-1300.
43. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy" score. J Natl Cancer Inst 2002; 94:1763-1772.
44. Gohagan J, Prorok P, Hayes R, Kramer B, for the PLCO Project. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21 (suppl):251S-272S.
45. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155-159.
46. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. J Natl Cancer Inst 1997; 89:1440-1448.
47. Zahl P, Strand B, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004; 328:921-924.
48. Berchi C, Bouvier V, Réaud J, Launoy G. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ 2004; 13:227-238.
49. Lejeune C, Arveux P, Dancourt V, Béjean S, Bonithon-Kopp C, Faivre J. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Tech Assess Health Care 2004; 20:434-439.
50. Flanagan W, Le Petit C, Berthelot J, White K, Coombs B, Jones-McLean E. Potential impact of population-based colorectal cancer screening in Canada. Chron Dis Can 2003; 24:81-88.
51. Helm J, Russo M, Biddle A, Simpson K, Ransohoff D, Sandler R. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol 2000; 95:3250-3258.
52. Rex D, Johnson D, Lieberman D, Burt R, Sonnenberg A. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol 2000; 95:868-877.
53. French Society of Gastroenterology. Prevention, screening and healthcare of colon cancer [in French]. Paris: Forum Rive-Gauche; 1998.
54. Spicak J, Schoefl R. Colorectal cancer screening programs in the central and eastern Europe. Endoscopy 2004; 36:97-100.
55. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationales - update based on new evidence. Gastroenterology 2003; 124:544-560.
56. Nadel M, Shapiro J, Klabunde C, Seeff L, Uhler R, Smith R, et al. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005; 142:86-94.
57. Schoen R, Weissfeld J, Trauth J, Ling B, Hayran M. A population-based, community estimate of total colon examination: the impact on compliance with screening for colorectal cancer. Am J Gastroenterol 2002; 97:446-451.
58. Salkeld G, Solomon M, Short L, Ryan M, Ward J. Evidence-based consumer choice: a case study in colorectal cancer screening. Aust NZ J Public Health 2003; 27:449-455.
59. Sheikh R, Kapre S, Calof O, Ward C. Screening preferences for colorectal cancer: a patient demographic study. Southern Med J 2004; 97:224-229.
60. Montano D, Selby J, Somkin C, Bhat A, Nadel M. Acceptance of flexible sigmoidoscopy screening for colorectal cancer. Cancer Detect Prev 2004; 28:43-51.
61. Turner B, Weiner M, Yang C, Tenhave T. Predicting adherence to colonoscopy or flexible sigmoidoscopy on the basis of physician appointment-keeping behaviour. Ann Intern Med 2004; 140:528-532.